Caractérisation moléculaire des cancers du sein en pratique clinique

Y. Zemmouri (1) , Diane de Croze (2) , Anne Vincent Salomon (3) , Roman Rouzier (4, 2) , Claire Bonneau (4, 3)

1 Département de chirurgie
2 Hôpital René Huguenin [Saint-Cloud]
3 Institut Curie [Paris]
4 RISCQ - Risques cliniques et sécurité en santé des femmes et en santé périnatale

Breast cancer involves various types of tumors. The objective of this review was to provide a summary of the main methods currently available in clinical practice to characterize breast cancers at a molecular level and to discuss their prognostic and predictive values. Hormonal receptors expression and the HER2 status are prognostic markers and can also predict the response to targeted therapies. Their analysis through immunohistochemistry is systematical. Ki67 is an effective prognostic marker, but its reliability is debated because of its low reproducibility between laboratories and between pathologists. Commercial genomic signatures are all considered valid prognostic tools and may guide physicians to make therapeutic choices. These signatures are costly and should therefore be restricted to situations in which the use of chemotherapy remains equivocal.

Mots clés: Breast cancer; Genomic signature; Molecular classification; Precision medicine

Domaines: Sciences du Vivant [q-bio]

Y. Zemmouri, Diane de Croze, Anne Vincent Salomon, Roman Rouzier, Claire Bonneau. Caractérisation moléculaire des cancers du sein en pratique clinique. Gynécologie Obstétrique & Fertilité, 2016, 44 (5), pp.285-292. ⟨10.1016/j.gyobfe.2016.03.010⟩. ⟨hal-02559116⟩